Bio Life Tech Venture Capital Conference In Brief
This article was originally published in The Gray Sheet
NeoDiagnostix: Cervical DNA Dtex Pap screening follow-up cervical cancer test will be directly marketed to clinical reference labs in 2006, bypassing the need for FDA approval, CEO Gregory Endress says Sept. 14 during the Bio Life Tech Venture Capital Conference in Baltimore, Md. The firm's test is targeted at the 3.5 mil. abnormal Pap tests recorded each year and is intended to complement existing HPV tests such as Ventana Medical'sInform, Cytyc's ThinPrep and Digene's DNAwithPap. Cervical Dtex is based on fluorescent in situ hybridization (FISH) technology, which the firm will also use in an oral cancer diagnostic by 2007. NeoDiagnostix expects revenues of $5 mil. in 2006...
You may also be interested in...
Genzyme is urging CMS to retain a single HCPCS procedure billing code for the three hyaluronic acid-based devices competing with its Synvisc
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.